Development of Apolipoprotein B Antisense Molecules as a Therapy for Hyperlipidemia
- 24 December 2009
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 12 (1) , 58-65
- https://doi.org/10.1007/s11883-009-0078-7
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Efficacy of statins in familial hypercholesterolaemia: a long term cohort studyBMJ, 2008
- Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic MiceCirculation, 2008
- Statin Safety: A Systematic ReviewThe American Journal of Cardiology, 2006
- Hepatic and Cardiovascular Consequences of Familial HypobetalipoproteinemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Antisense oligonucleotides as therapeutics for hyperlipidaemiasExpert Opinion on Biological Therapy, 2005
- Fatty liver in familial hypobetalipoproteinemiaJournal of Lipid Research, 2004
- Fatty liver in familial hypobetalipoproteinemia: triglyceride assembly into VLDL particles is affected by the extent of hepatic steatosisJournal of Lipid Research, 2003
- The Role of the Microsomal Triglygeride Transfer Protein in AbetalipoproteinemiaAnnual Review of Nutrition, 2000
- Targeted Disruption of the Mouse apobec-1 Gene Abolishes Apolipoprotein B mRNA Editing and Eliminates Apolipoprotein B48Journal of Biological Chemistry, 1996
- Familial defective apolipoprotein B-100: detection in the United Kingdom and Scandinavia, and clinical characteristics of ten casesAtherosclerosis, 1990